Actinogen Reaches Recruitment Milestone in XanaMIA Alzheimer's Trial with Interim Analysis Set for 2026 Actinogen Medical has enrolled its 100th participant in the XanaMIA trial for Alzheimer's disease, with key interim analysis planned for January 2026.

Actinogen Reaches Recruitment Milestone in XanaMIA Alzheimer's Trial with Interim Analysis Set for 2026 #Australia #Sydney #Alzheimer's_Disease #Actinogen #XanaMIA